Changes in medical oncology admissions for the management of breast cancer complications: An Australian institution's experience

被引:4
作者
Day, Fiona L. [1 ]
Bull, James M. [1 ]
Lombard, Janine M. [1 ]
Stewart, John F. [1 ]
机构
[1] Calvary Mater Newcastle Hosp, Dept Med Oncol, Reg Mail Ctr, Sydney, NSW, Australia
关键词
brain metastasis; breast cancer; hospitalization; length of stay; NERVOUS-SYSTEM METASTASES; BRAIN METASTASES; POSTMENOPAUSAL WOMEN; PHASE-III; TRASTUZUMAB; RISK; PEGFILGRASTIM; CHEMOTHERAPY; FILGRASTIM; TAMOXIFEN;
D O I
10.1111/j.1743-7563.2011.01391.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: There is a scarcity of data regarding medical hospitalizations for breast cancer. The aim was to determine whether the burden of inpatient care for breast cancer was declining. Methods: A retrospective study was conducted of all admissions to a single medical oncology inpatient unit in 1996 and 2006 related to the treatment of breast cancer. The total number of hospitalizations, patients' length of stay in hospital, clinical indications for hospitalization and utilization of inpatient services were determined. Data analysis involved pairwise comparisons between the cohorts. Results: The total number of breast cancer hospitalizations was similar in 1996 and 2006. However, the number of hospitalizations for adjuvant treatment complications was 50% lower in 2006, attributable to a lower rate of chemotherapy-associated febrile neutropenia. Acute clinical problems necessitating inpatient care differed between 1996 and 2006. Fewer hospitalizations for symptomatic hypercalcemia, uncontrolled pain and chemotherapy toxicity were required in 2006 but a significant increase was seen in central nervous system complications. Recent practice involved greater inpatient consultation of other medical and surgical teams. There was a trend towards a shorter duration of admissions in 2006 in both adjuvant and metastatic patients. Conclusion: Although total annual breast cancer admission numbers and length of stay did not change significantly, hospitalization for treatment-related complications was less frequent in 2006. The clinical manifestations of metastatic breast cancer appear to be changing, and in our institution are being managed with broader multidisciplinary care.
引用
收藏
页码:146 / 153
页数:8
相关论文
共 32 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Association between unplanned readmission rate and volume of breast cancer operation cases
    Ahn, HS
    Yoon, SJ
    Jo, HY
    Lee, HY
    Lee, J
    Seo, HJ
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (01) : 32 - 35
  • [3] Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
    Bendell, JC
    Domchek, SM
    Burstein, HJ
    Harris, L
    Younger, J
    Kuter, I
    Bunnell, C
    Rue, M
    Gelman, R
    Winer, E
    [J]. CANCER, 2003, 97 (12) : 2972 - 2977
  • [4] Increasing 'active prevalence' of cancer in Western Australia and its implications for health services
    Brameld, KJ
    Holman, CDJ
    Threlfall, TJ
    Lawrence, DM
    De Klerk, NH
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2002, 26 (02) : 164 - 169
  • [5] *CANC COUNC VICT, 2010, CANSTAT DIG FACTS FI
  • [6] *CANC I NSW, 2010, CANC INC NEW S WAL I
  • [7] *DEP HLTH AG ROUND, 2007, COST REP PUBL VERS 5
  • [8] Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer
    Du, XLL
    Osborne, C
    Goodwin, JS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) : 4636 - 4642
  • [9] Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
    Fong, Peter C.
    Boss, David S.
    Yap, Timothy A.
    Tutt, Andrew
    Wu, Peijun
    Mergui-Roelvink, Marja
    Mortimer, Peter
    Swaisland, Helen
    Lau, Alan
    O'Connor, Mark J.
    Ashworth, Alan
    Carmichael, James
    Kaye, Stan B.
    Schellens, Jan H. M.
    de Bono, Johann S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) : 123 - 134
  • [10] Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Geyer, Charles E.
    Forster, John
    Lindquist, Deborah
    Chan, Stephen
    Romieu, C. Gilles
    Pienkowski, Tadeusz
    Jagiello-Gruszfeld, Agnieszka
    Crown, John
    Chan, Arlene
    Kaufman, Bella
    Skarlos, Dimosthenis
    Campone, Mario
    Davidson, Neville
    Berger, Mark
    Oliva, Cristina
    Rubin, Stephen D.
    Stein, Steven
    Cameron, David
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) : 2733 - 2743